GLP-1 Medications and Heart Health: Cardiovascular Benefits Beyond Weight Loss
GLP-1 receptor agonists like semaglutide and liraglutide reduce major cardiovascular events, stroke, and heart failure risk—independent of weight loss alone. Here's what the evidence shows.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on March 30, 2026
Our medical review process ensures clinical accuracy and patient safety.
When GLP-1 receptor agonists first entered the obesity treatment landscape, the conversation centered almost entirely on weight loss. That framing has since shifted dramatically. A series of landmark cardiovascular outcomes trials — culminating in the 2023 SELECT trial — has established that these medications do something far more consequential than shrinking waistlines: they reduce the risk of heart attack, stroke, and cardiovascular death in patients who carry the greatest cardiac risk.
For clinicians and patients weighing GLP-1 therapy, these data represent a fundamental change in how the drugs should be evaluated. Weight loss is still meaningful, but it is no longer the headline.
The SELECT Trial: A Turning Point for Non-Diabetic Patients
The most consequential evidence came from the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial, published in the New England Journal of Medicine in November 2023.
Evidence: "In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (6.5% vs. 8.0%; HR 0.80; 95% CI, 0.72–0.90; P<0.001)." — Lincoff AM, et al. N Engl J Med. 2023. DOI: 10.1056/NEJMoa2307563
The trial enrolled 17,604 adults — none with diabetes — who had a body mass index ≥27 and established cardiovascular disease (prior myocardial infarction, stroke, or peripheral arterial disease). Over a mean follow-up of 39.8 months, weekly semaglutide 2.4 mg reduced the primary composite endpoint of major adverse cardiovascular events (MACE) by 20% compared to placebo.
What makes SELECT particularly significant is what it does not require for benefit: the participants had no diabetes diagnosis. Prior to this trial, the cardiovascular case for GLP-1 drugs rested entirely on studies in diabetic populations. SELECT closed that gap. Obesity itself, combined with pre-existing cardiovascular disease, was sufficient to confer meaningful cardiac protection from semaglutide.
The absolute risk reduction was modest — 1.5 percentage points over roughly three years — but given the size of the population affected by cardiovascular disease and obesity, the public health implications are substantial.
Earlier Trials in Diabetic Populations: LEADER and SUSTAIN-6
The cardiovascular story for GLP-1 drugs began years before SELECT, with trials conducted in patients with type 2 diabetes and elevated cardiac risk.
LEADER: Liraglutide Across 9,340 Patients
The LEADER trial randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide 1.8 mg or placebo for a median of 3.8 years.
Evidence: "The rate of first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke was significantly lower in the liraglutide group than in the placebo group (13.0% vs. 14.9%; HR 0.87; 95% CI, 0.78–0.97; P<0.001 for noninferiority; P=0.01 for superiority)." — Marso SP, et al. N Engl J Med. 2016. DOI: 10.1056/NEJMoa1603827
Liraglutide reduced MACE by 13%, with the benefit driven primarily by fewer cardiovascular deaths. The drug also reduced the rate of kidney disease progression — an early signal that the protective effects extended beyond the heart.
SUSTAIN-6: Semaglutide in Diabetic Patients
SUSTAIN-6 evaluated semaglutide in 3,297 patients with type 2 diabetes and high cardiovascular risk across a 104-week period.
Evidence: "The rate of first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke was significantly lower in the semaglutide group than in the placebo group (6.6% vs. 8.9%; HR 0.74; 95% CI, 0.58–0.95; P<0.001 for noninferiority)." — Marso SP, et al. N Engl J Med. 2016. DOI: 10.1056/NEJMoa1607141
Semaglutide produced a 26% relative risk reduction in MACE. Notably, the reduction in nonfatal stroke was especially pronounced (HR 0.61), a finding that distinguished semaglutide from some other agents in the class.
What Meta-Analyses Tell Us: Benefits Across the Class
Individual trials inevitably raise the question of whether findings are drug-specific or class-wide. Recent meta-analyses point toward the latter.
A 2024 meta-analysis in Clinical Cardiology pooled 24 randomized controlled trials involving more than 94,500 participants and examined MACE outcomes in patients with and without diabetes.
Evidence: "GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events (RR 0.87; 95% CI, 0.82–0.93), cardiovascular death (RR 0.88), myocardial infarction (RR 0.87), stroke (RR 0.86), and hospitalization for heart failure (RR 0.90). Benefits were observed in both diabetic and non-diabetic subgroups." — Clin Cardiol. 2024;47(7):e24314. DOI: 10.1002/clc.24314
A separate analysis published in The Lancet Diabetes & Endocrinology in late 2024 — covering 11 trials and 85,373 participants — reported GLP-1 RAs reduced MACE by 13% and all-cause mortality by 12% in patients with type 2 diabetes, while simultaneously cutting the composite kidney outcome by 18%.
Evidence: "GLP-1 receptor agonists reduced MACE by 13%, all-cause death by 12%, composite kidney outcomes by 18%, and kidney failure by 16% across 11 randomized trials in patients with type 2 diabetes." — Badve SV, et al. Lancet Diabetes Endocrinol. 2024. DOI: 10.1016/S2213-8587(24)00271-7
The consistency across trials, drug agents, and patient populations is striking. GLP-1 receptor agonism appears to carry cardiovascular benefits that are not reducible to a single molecule or a single patient type.
How Do GLP-1 Drugs Protect the Heart?
The mechanisms underlying these cardiovascular benefits are not fully characterized, but several pathways have been identified in preclinical and clinical research:
Direct cardiac and vascular effects. GLP-1 receptors are expressed in the heart, vasculature, and kidneys. Receptor activation promotes anti-inflammatory and anti-atherosclerotic effects in endothelial cells, independent of systemic metabolic changes.
Weight loss. Semaglutide 2.4 mg produces roughly 15% body weight reduction at 68 weeks in the STEP-1 trial cohort. Adipose tissue reduction lowers systemic inflammation, blood pressure, and lipid levels — each a contributor to cardiovascular risk. However, SELECT subgroup analyses suggest the cardiovascular benefit exceeded what would be predicted from weight loss alone, indicating direct drug effects.
Blood pressure and lipid improvement. GLP-1 agonists consistently lower systolic blood pressure by 2–5 mmHg and modestly improve triglycerides and HDL cholesterol in clinical trials.
Reduced inflammation. C-reactive protein and other inflammatory markers fall with GLP-1 therapy. Atherosclerotic plaque progression is inflammatory in nature, and reducing systemic inflammation may directly slow plaque accumulation.
Kidney protection. Preserved renal function reduces the cardiovascular burden associated with chronic kidney disease, creating a secondary benefit loop.
Who Benefits Most?
The current evidence is most robust for patients who already have established cardiovascular disease. The SELECT trial specifically required a prior cardiovascular event for enrollment, and the ACC/AHA obesity management guidelines now reflect the cardiovascular outcome data when considering GLP-1 drugs in high-risk patients.
For patients with type 2 diabetes, American Diabetes Association guidelines already recommend GLP-1 RAs with proven cardiovascular benefit (semaglutide, liraglutide) when established atherosclerotic cardiovascular disease is present — regardless of glycemic control needs.
For patients without established CVD but with high cardiovascular risk factors (hypertension, dyslipidemia, family history, smoking), the evidence base is less direct. The SELECT trial required prior CVD; whether equivalent protection extends to primary prevention populations remains under study.
If you are considering GLP-1 therapy, understanding how these medications work and what to expect when starting treatment provides important clinical context.
Limitations and Unanswered Questions
The trials to date have important boundaries:
- Follow-up duration. Most trials ran 2–4 years. Whether benefits persist, grow, or diminish over a decade is unknown.
- Primary prevention. SELECT required pre-existing CVD. The drug's cardiovascular role for patients without a prior event needs further study.
- Drug discontinuation. Weight regain after stopping GLP-1 therapy is well-documented; whether cardiovascular benefit is similarly lost is not yet established.
- Tirzepatide. The dual GIP/GLP-1 agonist tirzepatide shows strong cardiometabolic data in the SURMOUNT-MMO outcomes trial (ongoing), but head-to-head cardiovascular outcome data against semaglutide are not yet available.
Key Takeaways
The cardiovascular benefits of GLP-1 receptor agonists are no longer a secondary consideration — they are central to the clinical rationale for these drugs in high-risk patients. The SELECT, LEADER, and SUSTAIN-6 trials collectively show consistent MACE reductions across semaglutide and liraglutide, in both diabetic and non-diabetic populations, with mechanisms that appear to extend beyond weight reduction alone.
For overweight or obese adults with established cardiovascular disease, GLP-1 therapy now carries a strong evidence base not just for body weight management, but for reducing the risk of the very events — heart attack, stroke, cardiovascular death — that drive mortality in this population.
Discussing cardiovascular risk with a cardiologist or endocrinologist before initiating therapy remains essential, particularly given drug costs, individual cardiovascular profiles, and the evolving evidence landscape.
References
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. DOI: 10.1056/NEJMoa2307563
Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. DOI: 10.1056/NEJMoa1603827
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. DOI: 10.1056/NEJMoa1607141
Soliman MNS, et al. Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials. Clin Cardiol. 2024;47(7):e24314. DOI: 10.1002/clc.24314
Badve SV, et al. Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Disease Outcomes: A Meta-Analysis of Randomised Controlled Trials. Lancet Diabetes Endocrinol. 2025;13(1):61–73. DOI: 10.1016/S2213-8587(24)00271-7
Last updated: 2026-03-30 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Emily Rodriguez
Senior Medical Writer, MPH, RD
Emily Rodriguez is a registered dietitian and public health specialist. She translates complex medical research into accessible, actionable content for patients and healthcare providers.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.